{"id":"ljpc-501","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5790832","moleculeType":null,"molecularWeight":"463.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LJPC-501 binds to the C5a receptor on immune cells, preventing the potent anaphylatoxin C5a from triggering excessive complement-mediated inflammation. By blocking this pathway, the drug reduces neutrophil activation and recruitment to sites of inflammation, thereby dampening the inflammatory cascade implicated in various acute and chronic conditions.","oneSentence":"LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:07.794Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Sepsis-related conditions"}]},"trialDetails":[{"nctId":"NCT06072508","phase":"NA","title":"Prognostic Interest of Vasorin in Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2023-07-03","conditions":"Sepsis, Acute Kidney Injury","enrollment":50},{"nctId":"NCT04901169","phase":"PHASE2, PHASE3","title":"Angiotensin II in Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-06-28","conditions":"Liver Transplant; Complications, Vasoplegia","enrollment":50},{"nctId":"NCT06746753","phase":"PHASE4","title":"Dysfunctional Renin-Angiotensin System in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-03","conditions":"Septic Shock","enrollment":78},{"nctId":"NCT06693726","phase":"PHASE4","title":"Early Angiotensin II in the Emergency Department","status":"RECRUITING","sponsor":"Brett A Faine","startDate":"2025-04-01","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT06588686","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.","status":"RECRUITING","sponsor":"Vicore Pharma AB","startDate":"2024-12-09","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":360},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT04456816","phase":"PHASE2","title":"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2020-08-31","conditions":"Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy","enrollment":23},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":"Heart Failure of Reduced Ejection Fraction (HFrEF)","enrollment":5000},{"nctId":"NCT06749418","phase":"EARLY_PHASE1","title":"Vascular Effects of High-Salt After Preeclampsia","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2025-01-02","conditions":"Preeclampsia, Preeclampsia Postpartum","enrollment":40},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT05183646","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","status":"RECRUITING","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2022-05-30","conditions":"FSGS","enrollment":286},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT07374484","phase":"","title":"Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2024-12-10","conditions":"Kidney Transplantation, Graft Survival, Angiotensin II Type 1 Receptor Antibody","enrollment":241},{"nctId":"NCT07355023","phase":"NA","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","status":"RECRUITING","sponsor":"Tri-Service General Hospital","startDate":"2026-01-01","conditions":"Left Ventricular (LV) Systolic Dysfunction","enrollment":5000},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT03806283","phase":"","title":"Mechanisms of Pregnancy Vascular Adaptations","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2018-11-20","conditions":"Pre-Eclampsia, Vascular Diseases","enrollment":166},{"nctId":"NCT06933706","phase":"PHASE2","title":"Losartan to Improve Outcomes After Multi-ligament Knee Injury","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-01","conditions":"Multi-ligament Knee Injury","enrollment":90},{"nctId":"NCT05834803","phase":"NA","title":"Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-26","conditions":"Renovascular Hypertension, Renovascular Hypertension With Renal Failure, Heart Failure","enrollment":80},{"nctId":"NCT07312292","phase":"PHASE2","title":"Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","status":"NOT_YET_RECRUITING","sponsor":"Niek Wijnen","startDate":"2026-01-01","conditions":"Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult","enrollment":15},{"nctId":"NCT06487585","phase":"PHASE4","title":"ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)","status":"RECRUITING","sponsor":"University of Maryland St. Joseph Medical Center","startDate":"2025-05-06","conditions":"Vasodilatory Hypotension During or After Cardiac Surgery","enrollment":100},{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-01-08","conditions":"Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":368},{"nctId":"NCT04752293","phase":"","title":"Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction","enrollment":125},{"nctId":"NCT01426529","phase":"PHASE1","title":"Caveolin-1 and Vascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-10-01","conditions":"Hypertension, Insulin Resistance","enrollment":120},{"nctId":"NCT07212686","phase":"PHASE4","title":"Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension","status":"ENROLLING_BY_INVITATION","sponsor":"Todd Sweberg","startDate":"2025-09-09","conditions":"Vasodilatory Shock","enrollment":30},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT06700213","phase":"","title":"Guideline Directed Medical Therapy in Patients With Heart Failure","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-22","conditions":"Heart Failure","enrollment":300},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT00962949","phase":"PHASE1","title":"The Renin-Aldosterone Axis in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-04","conditions":"Postural Orthostatic Tachycardia Syndrome (POTS)","enrollment":28},{"nctId":"NCT04520048","phase":"NA","title":"Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-08-11","conditions":"Hypertension Disorders in Pregnancy, Gestational Hypertension, Pre-Eclampsia","enrollment":110},{"nctId":"NCT04592744","phase":"PHASE4","title":"Angiotensin 2 for AKI After OLT","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2022-04-08","conditions":"Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury","enrollment":30},{"nctId":"NCT03733145","phase":"PHASE4","title":"Angiotensin II in General Anesthesia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-10-03","conditions":"Hypertension","enrollment":32},{"nctId":"NCT05937841","phase":"EARLY_PHASE1","title":"Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-06-28","conditions":"Preeclampsia Postpartum","enrollment":30},{"nctId":"NCT05331144","phase":"PHASE2","title":"Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","status":"RECRUITING","sponsor":"Rong Zhang","startDate":"2022-10-25","conditions":"Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline","enrollment":180},{"nctId":"NCT06150560","phase":"PHASE3","title":"A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-01","conditions":"Coarctation of Aorta, High Blood Pressure","enrollment":120},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT04715568","phase":"PHASE4","title":"Secondhand Tobacco Smoke and Cardiovascular Disease","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-03-30","conditions":"Cardiovascular Diseases, Hypertension","enrollment":100},{"nctId":"NCT06615102","phase":"PHASE3","title":"Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II","status":"RECRUITING","sponsor":"Universität Münster","startDate":"2025-03-31","conditions":"Cardiac Surgery, Vasoplegia","enrollment":1022},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT01679132","phase":"NA","title":"BAROSTIM NEO Hypertension Pivotal Trial","status":"SUSPENDED","sponsor":"CVRx, Inc.","startDate":"2013-04-12","conditions":"Uncontrolled Hypertension","enrollment":10},{"nctId":"NCT04632589","phase":"EARLY_PHASE1","title":"Losartan for Improved Vascular Endothelial Function After Preeclampsia","status":"COMPLETED","sponsor":"Anna Stanhewicz, PhD","startDate":"2020-11-22","conditions":"Preeclampsia Postpartum","enrollment":11},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":80},{"nctId":"NCT03354143","phase":"PHASE2","title":"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-04-10","conditions":"Hypertension","enrollment":85},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT03482440","phase":"EARLY_PHASE1","title":"Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2018-08-26","conditions":"Preeclampsia","enrollment":24},{"nctId":"NCT06964217","phase":"","title":"Immediate Fracture Risk After Antihypertensive Drug Initiation","status":"NOT_YET_RECRUITING","sponsor":"Ajou University School of Medicine","startDate":"2025-06-01","conditions":"Hypertension, Fracture","enrollment":10000000},{"nctId":"NCT06625346","phase":"","title":"Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.","status":"RECRUITING","sponsor":"The Searle Company Limited Pakistan","startDate":"2024-09-28","conditions":"Hypertension","enrollment":420},{"nctId":"NCT06838416","phase":"","title":"Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-17","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Renal Function","enrollment":300},{"nctId":"NCT06234592","phase":"NA","title":"The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-01-05","conditions":"Septic Shock, Acute Kidney Injury","enrollment":45},{"nctId":"NCT00429364","phase":"PHASE3","title":"Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2007-01","conditions":"Marfan Syndrome","enrollment":608},{"nctId":"NCT02560805","phase":"PHASE2","title":"Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV","status":"SUSPENDED","sponsor":"Emory University","startDate":"2015-10","conditions":"Stress Disorders, Post-Traumatic","enrollment":134},{"nctId":"NCT03310684","phase":"","title":"Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-12-03","conditions":"Pediatric Disorder, Pediatric Obesity, Primary Hypertension","enrollment":35},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT05427253","phase":"PHASE1","title":"First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2022-06-08","conditions":"Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis","enrollment":80},{"nctId":"NCT06351150","phase":"PHASE3","title":"Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07-23","conditions":"Vasodilatory Shock","enrollment":214},{"nctId":"NCT05759754","phase":"NA","title":"Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2023-09-17","conditions":"Proteinuria, Kidney Diseases, Hereditary Nephropathy","enrollment":72},{"nctId":"NCT06654596","phase":"NA","title":"Efficacy and Safety of Telitacicept in IgAN","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-06","conditions":"IgA Nephropathy (IgAN), Kidney Diseases, Telitacicept","enrollment":118},{"nctId":"NCT06157580","phase":"EARLY_PHASE1","title":"Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia","status":"COMPLETED","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-12-08","conditions":"Preeclampsia","enrollment":24},{"nctId":"NCT04768322","phase":"NA","title":"LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-02-24","conditions":"End-stage Heart Failure","enrollment":92},{"nctId":"NCT04913870","phase":"PHASE4","title":"Angiotensin Receptor Blockers in Aortic Stenosis","status":"RECRUITING","sponsor":"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","startDate":"2020-02-01","conditions":"Aortic Stenosis, Aortic Valve Stenosis","enrollment":144},{"nctId":"NCT05831644","phase":"PHASE1","title":"A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2023-03-31","conditions":"Type2diabetes, Endothelial Dysfunction","enrollment":11},{"nctId":"NCT05709444","phase":"PHASE2","title":"A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2022-12-26","conditions":"Kidney Disease","enrollment":16},{"nctId":"NCT04558359","phase":"PHASE4","title":"Renin and Renal Biomarker Response to Angiotensin II","status":"COMPLETED","sponsor":"Alexander Flannery","startDate":"2020-10-19","conditions":"Septic Shock, Acute Kidney Injury","enrollment":30},{"nctId":"NCT05637216","phase":"PHASE2","title":"Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients","status":"RECRUITING","sponsor":"Shaw Cancer Center","startDate":"2023-08-17","conditions":"Radiation Induced Fibrosis","enrollment":40},{"nctId":"NCT05164653","phase":"PHASE4","title":"Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saga University","startDate":"2021-12-27","conditions":"Heart Failure","enrollment":400},{"nctId":"NCT06539234","phase":"","title":"Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II.","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2024-08-01","conditions":"Shock, Vasoplegic Syndrome","enrollment":80},{"nctId":"NCT06501651","phase":"PHASE4","title":"Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2024-08-01","conditions":"Essential Hypertension, Type 2 Diabetes, Nephropathy","enrollment":297},{"nctId":"NCT06122987","phase":"PHASE4","title":"Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock","status":"RECRUITING","sponsor":"Kingman Regional Medical Center","startDate":"2023-12-04","conditions":"Septic Shock, Shock, Sepsis","enrollment":50},{"nctId":"NCT05269615","phase":"PHASE4","title":"Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2023-03-20","conditions":"Exercise Physiology","enrollment":80},{"nctId":"NCT01393782","phase":"PHASE1","title":"Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study","status":"COMPLETED","sponsor":"George Washington University","startDate":"2011-07","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT05818995","phase":"","title":"Therapeutic Drug Use for CKD Patients","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2022-07-01","conditions":"Chronic Kidney Disease","enrollment":10000},{"nctId":"NCT05193370","phase":"PHASE4","title":"Angiotensin II vs. Vasopressin in Septic Shock","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2022-01-03","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT04048707","phase":"PHASE2","title":"Angiotensin 2 for Hepatorenal Syndrome","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-07-01","conditions":"Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute","enrollment":""},{"nctId":"NCT02597361","phase":"PHASE3","title":"Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01","conditions":"Ehlers-Danlos Syndrome, Vascular Type","enrollment":61},{"nctId":"NCT06278727","phase":"","title":"Development and Validation of the Prediction Model for Functional Mitral Regurgitation Regression in Heart Failure Patients Taking Guideline-directed Medical Therapy","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-01","conditions":"Mitral Regurgitation, Heart Failure","enrollment":270},{"nctId":"NCT05055570","phase":"","title":"Angiotensin II Pathway and Postoperative Hypoxemia","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2021-08-12","conditions":"Aortic Dissection","enrollment":88},{"nctId":"NCT06013839","phase":"PHASE2","title":"TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy","status":"UNKNOWN","sponsor":"Constant Therapeutics LLC","startDate":"2023-08-31","conditions":"DMD-Associated Dilated Cardiomyopathy","enrollment":10},{"nctId":"NCT02351063","phase":"NA","title":"HF Assessment With BNP in the Home: Part II","status":"TERMINATED","sponsor":"Alere San Diego","startDate":"2014-04","conditions":"Heart Failure","enrollment":1},{"nctId":"NCT03164785","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2017-07-24","conditions":"Type 2 Diabetes Mellitus, Diabetic Kidney Disease","enrollment":202},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Diabetic Kidney Disease","enrollment":70},{"nctId":"NCT06135103","phase":"PHASE2","title":"Phase 2 Study of TXA127 in Post-ischemic Stroke Patients","status":"UNKNOWN","sponsor":"Constant Therapeutics LLC","startDate":"2023-11-26","conditions":"Ischemic Stroke","enrollment":50},{"nctId":"NCT05893108","phase":"PHASE1, PHASE2","title":"Ethosomal Gel Bearing Losartan 5% for Keloid Treatment","status":"UNKNOWN","sponsor":"Yuni Eka Anggraini","startDate":"2024-03-30","conditions":"Keloid","enrollment":46},{"nctId":"NCT05157464","phase":"PHASE4","title":"Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2023-09-01","conditions":"Arthrofibrosis","enrollment":""},{"nctId":"NCT04778059","phase":"PHASE2","title":"Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19","status":"TERMINATED","sponsor":"US Biotest, Inc.","startDate":"2021-07-27","conditions":"2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection","enrollment":21},{"nctId":"NCT04904562","phase":"PHASE4","title":"Angiotensin II for Distributive Shock","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2022-06-01","conditions":"Distributive Shock","enrollment":40},{"nctId":"NCT03951142","phase":"PHASE2","title":"Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study","status":"UNKNOWN","sponsor":"Kyrre Eeg Emblem","startDate":"2019-10-01","conditions":"Glioblastoma, Brain Metastases","enrollment":165},{"nctId":"NCT05260658","phase":"PHASE1","title":"Safety and Tolerability of CFTX-1554 in Healthy Subjects","status":"COMPLETED","sponsor":"Confo Therapeutics","startDate":"2022-02-09","conditions":"Healthy","enrollment":97},{"nctId":"NCT05212649","phase":"","title":"Optimized Peak VO2 in Predicting Advanced HF","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2014-05-01","conditions":"Heart Failure, Morality, Transplant; Failure, Heart","enrollment":377},{"nctId":"NCT02364089","phase":"NA","title":"Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-04-09","conditions":"Adrenal Incidentalomas","enrollment":78},{"nctId":"NCT04766645","phase":"","title":"ACE2 Gender Differences in Stroke With COVID-19","status":"COMPLETED","sponsor":"Fondazione Don Carlo Gnocchi Onlus","startDate":"2020-09-04","conditions":"Neurologic Manifestations","enrollment":77},{"nctId":"NCT03552575","phase":"PHASE3","title":"The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-07-01","conditions":"Heart Failure","enrollment":93},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT00309257","phase":"PHASE2","title":"Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2004-01","conditions":"Alport Syndrome","enrollment":9},{"nctId":"NCT05199493","phase":"PHASE3","title":"Reducing Acute Kidney Injury Occurence by Administering Angiotensin II","status":"COMPLETED","sponsor":"Universität Münster","startDate":"2021-12-27","conditions":"Cardiac Surgery, Vasoplegia, Hyperreninemia","enrollment":64},{"nctId":"NCT03315832","phase":"PHASE2, PHASE3","title":"Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study","status":"WITHDRAWN","sponsor":"University Hospital, Limoges","startDate":"2023-01-02","conditions":"Aortic Valve Stenosis, Valsartan, Angiotensin Receptor Antagonists","enrollment":""},{"nctId":"NCT03217825","phase":"PHASE2","title":"Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2015-12","conditions":"Hypertension","enrollment":240},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":"Covid19, SARS-CoV Infection","enrollment":341},{"nctId":"NCT02188121","phase":"PHASE4","title":"Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2015-02","conditions":"Serious Mental Illness, Schizophrenia, Schizoaffective Disorder","enrollment":227},{"nctId":"NCT04351581","phase":"NA","title":"Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2020-05-18","conditions":"Covid-19","enrollment":78},{"nctId":"NCT04529005","phase":"PHASE4","title":"Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2020-08-13","conditions":"Shock, Surgical, Shock, Hypotension and Shock","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["angiotensin II"],"phase":"phase_3","status":"active","brandName":"LJPC-501","genericName":"LJPC-501","companyName":"La Jolla Pharmaceutical Company","companyId":"la-jolla-pharmaceutical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment. Used for Acute respiratory distress syndrome (ARDS), Sepsis-related conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}